Key result
Antiplatelet agents in diabetic patients after amputation for gangrene yielded negative overall results, with suggestive findings in cerebrovascular disease and sudden death subgroups.
Why the study?
Do antiplatelet agents improve outcomes in diabetic patients after amputation for gangrene?
Do antiplatelet agents improve outcomes in diabetic patients after amputation for gangrene?
Answers are grounded in this paper and cite their sources.
This review of a negative VA trial of antiplatelet agents in diabetic amputees discusses methodological challenges and potential subgroup effects.
This paper review some of the issues faced by the investigators involved in a VA Cooperative Study on Antiplatelet Agents in Diabetic Patients after Amputation for Gangrene. The study was a negative one, and some of the reasons for this are considered. In addition, suggestive results in two subgroups, cerebrovascular disease and unexpected, sudden, or unobserved deaths, were found. The implications and interpretation of these findings are discussed.
No takes yet. Share an insight, caveat, or question.
Colwell et al. (2009) conducted a review in Diabetic patients after amputation for gangrene. Antiplatelet Agents was evaluated. Antiplatelet agents in diabetic patients after amputation for gangrene yielded negative overall results, with suggestive findings in cerebrovascular disease and sudden death subgroups.
Synapse has enriched 10 related papers. Consider them for comparative context: